These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19765611)

  • 1. Detection of low level histamine H3 receptor occupancy by autoradiography.
    Le S; Finn JP; Larijani ME; Marino MJ; Schaffhauser H
    J Neurosci Methods; 2009 Dec; 185(1):70-5. PubMed ID: 19765611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
    Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
    J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
    Mezzomo K; Cumming P; Minuzzi L
    Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.
    Tedford CE; Yates SL; Pawlowski GP; Nalwalk JW; Hough LB; Khan MA; Phillips JG; Durant GJ; Frederickson RC
    J Pharmacol Exp Ther; 1995 Nov; 275(2):598-604. PubMed ID: 7473144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.
    Ligneau X; Garbarg M; Vizuete ML; Diaz J; Purand K; Stark H; Schunack W; Schwartz JC
    J Pharmacol Exp Ther; 1994 Oct; 271(1):452-9. PubMed ID: 7965746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a histamine H3 receptor model through structure-activity relationships for classical H3 antagonists.
    Lorenzi S; Mor M; Bordi F; Rivara S; Rivara M; Morini G; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
    Bioorg Med Chem; 2005 Oct; 13(19):5647-57. PubMed ID: 16085419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosynthesis and biodistribution of a histamine H3 receptor antagonist 4-[3-(4-piperidin-1-yl-but-1-ynyl)-[11C]benzyl]-morpholine: evaluation of a potential PET ligand.
    Airaksinen AJ; Jablonowski JA; van der Mey M; Barbier AJ; Klok RP; Verbeek J; Schuit R; Herscheid JD; Leysen JE; Carruthers NI; Lammertsma AA; Windhorst AD
    Nucl Med Biol; 2006 Aug; 33(6):801-10. PubMed ID: 16934699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
    Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
    Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical validation of a novel alpha-7 nicotinic receptor radiotracer, [(3)H]AZ11637326: target localization, biodistribution and ligand occupancy in the rat brain.
    Maier DL; Hill G; Ding M; Tuke D; Einstein E; Gurley D; Gordon JC; Bock MJ; Smith JS; Bialecki R; Eisman M; Elmore CS; Werkheiser JL
    Neuropharmacology; 2011; 61(1-2):161-71. PubMed ID: 21497612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postnatal development and kinetics of [3H]gaboxadol binding in rat brain: in vitro homogenate binding and quantitative autoradiography.
    Friemel A; Ebert B; Hutson PH; Brust P; Nieber K; Deuther-Conrad W
    Brain Res; 2007 Sep; 1170():39-47. PubMed ID: 17692833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
    Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
    Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
    Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons.
    Dai H; Fu Q; Shen Y; Hu W; Zhang Z; Timmerman H; Leurs R; Chen Z
    Eur J Pharmacol; 2007 Jun; 563(1-3):117-23. PubMed ID: 17350613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.